Considerations for successful cancer immunotherapy in aged hosts

Clinical and Experimental Immunology

Volumn 187, Issue 1, 2017, Pages 53-63

  Hurez, V ^a   Padron A S ^a   Svatek, R S ^b,c   Curiel, T J ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

Author keywords

aging; cancer; immunity; immunotherapy

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST;

AGE RELATED IMMUNE DYSFUNCTION; AGED; AUTOIMMUNE DISEASE; CALORIC RESTRICTION; CANCER IMMUNOTHERAPY; CELL POPULATION; CELL TRANSFER; CYTOKINE PRODUCTION; DENDRITIC CELL; HOST; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; IMMUNOTOXICITY; INNATE IMMUNITY; MACROPHAGE; MICROBIOME; MYELOID-DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; AGING; ANIMAL; IMMUNOLOGY; IMMUNOSENESCENCE; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

AGED; AGING; ANIMALS; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOSENESCENCE; IMMUNOTHERAPY; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84999036725     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12875     Document Type: Review

References (111)

1. Pardoll D. T cells and tumours. Nature 2001; 411:1010–2.
2. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21:807–39.
3. Bouchlaka MN, Murphy WJ. Impact of aging in cancer immunotherapy: the importance of using accurate preclinical models. Oncoimmunology 2013; 2:e27186.
4. Bouchlaka MN, Sckisel GD, Chen M et al. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med 2013; 210:2223–37.
5. Hurez V, Daniel BJ, Sun L et al. Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res 2012; 72:2089–99.
6. Kaur A, Webster MR, Marchbank K et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 2016; 532:250–4.
7. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565–70.
8. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329–60.
9. Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903–7.
10. Matsushita H, Vesely MD, Koboldt DC et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400–4.
11. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482:405–9.
12. Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol 2010; 11:790–6.
13. Stephens JK, Everson GT, Elliott CL et al. Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. Transplantation 2000; 70:232–6.
14. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57–70.
15. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21:297–308.
16. Demaria S, Pikarsky E, Karin M et al. Cancer and inflammation: promise for biologic therapy. J Immunother 2010; 33:335–51.
17. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883–99.
18. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30:1073–81.
19. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability – an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11:220–8.
20. De Bock K, Cauwenberghs S, Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 2010; 21:73–9.
21. Teschendorff AE, Menon U, Gentry-Maharaj A et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 2010; 20:440–6.
22. Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE. Aging, immunity and cancer. Curr Opin Immunol 2004; 16:151–6.
23. Haynes BF, Sempowski GD, Wells AF, Hale LP. The human thymus during aging. Immunol Res 2000; 22:253–61.
24. Goldberg EL, Romero-Aleshire MJ, Renkema KR et al. Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms. Aging Cell 2015; 14:130–8.
25. Yang H, Youm YH, Vandanmagsar B et al. Obesity accelerates thymic aging. Blood 2009; 114:3803–12.
26. Surh CD, Boyman O, Purton JF, Sprent J. Homeostasis of memory T cells. Immunol Rev 2006; 211:154–63.
27. Anderlini P, Przepiorka D, Seong C et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997; 37:507–12.
28. Fulop T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol 2013; 4:271.
29. Fulop T, Witkowski JM, Le Page A, Fortin C, Pawelec G, Larbi A. Intracellular signalling pathways: targets to reverse immunosenescence. Clin Exp Immunol 2016.
30. Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol 2004; 172:5194.
31. Bansal-Pakala P, Croft M. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J Immunol 2002; 169:5005.
32. Ruby CE, Weinberg AD. OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. J Immunol 2009; 182:1481–9.
33. Ruby CE, Weinberg AD. The effect of aging on OX40 agonist-mediated cancer immunotherapy. Cancer Immunol Immunother 2009; 58:1941–7.
34. Lustgarten J, Dominguez AL, Thoman M. Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 2004; 173:4510–5.
35. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167–74.
36. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20:241–6.
37. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942.
38. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295–307.
39. Zhang H, Podojil JR, Luo X, Miller SD. Intrinsic and induced regulation of the age-associated onset of spontaneous experimental autoimmune encephalomyelitis. J Immunol 2008; 181:4638–47.
40. Rosenkranz D, Weyer S, Tolosa E et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 2007; 188:117–27.
41. Zhao L, Sun L, Wang H, Ma H, Liu G, Zhao Y. Changes of CD4+CD25+Foxp3+ regulatory T cells in aged Balb/c mice. J Leukoc Biol 2007; 81:1386–94.
42. Kryczek I, Liu R, Wang G et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69:3995–4000.
43. Kozlowska E, Biernacka M, Ciechomska M, Drela N. Age-related changes in the occurrence and characteristics of thymic CD4(+) CD25(+) T cells in mice. Immunology 2007; 122:445–53.
44. Thomas DC, Mellanby RJ, Phillips JM, Cooke A. An early age-related increase in the frequency of CD4+ Foxp3+ cells in BDC2.5NOD mice. Immunology 2007; 121:565–76.
45. Sun L, Hurez VJ, Thibodeaux SR et al. Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells. Aging Cell 2012; 11:509–19.
46. Lages CS, Suffia I, Velilla PA et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol 2008; 181:1835–48.
47. Tsaknaridis L, Spencer L, Culbertson N et al. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res 2003; 74:296–308.
48. Garg SK, Delaney C, Toubai T et al. Aging is associated with increased regulatory T-cell function. Ageing Cell 2014; 13:441–8.
49. Fessler J, Ficjan A, Duftner C, Dejaco C. The impact of aging on regulatory T-cells. Front Immunol 2013; 4:231.
50. Gregg R, Smith CM, Clark FJ et al. The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol 2005; 140:540–6.
51. Hwang KA, Kim HR, Kang I. Aging and human CD4(+) regulatory T cells. Mech Ageing Dev 2009; 130:509–17.
52. Dominguez AL, Lustgarten J. Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res 2008; 68:5423–31.
53. Sharma S, Dominguez AL, Lustgarten J. High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol 2006; 177:8348–55.
54. Jackaman C, Dye DE, Nelson DJ. IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice. Age (Dordr) 2014; 36:9655.
55. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265–77.
56. Zou W, Machelon V, Coulomb-L'Hermin A et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7:1339–46.
57. Curiel TJ, Wei S, Dong H et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9:562–7.
58. Agrawal A, Agrawal S, Tay J, Gupta S. Biology of dendritic cells in aging. J Clin Immunol 2008; 28:14–20.
59. Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW. The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol 2012; 31:246–66.
60. Tang YC, Thoman M, Linton PJ, Deisseroth A. Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged. Cancer Immunol Immunother 2009; 58:1949–57.
61. Geiger H, Rudolph KL. Aging in the lympho-hematopoietic stem cell compartment. Trends Immunol 2009; 30:360–5.
62. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436–44.
63. Jackaman C, Radley-Crabb HG, Soffe Z, Shavlakadze T, Grounds MD, Nelson DJ. Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice. Aging Cell 2013; 12:345–57.
64. Mahbub S, Deburghgraeve CR, Kovacs EJ. Advanced age impairs macrophage polarization. J Interferon Cytokine Res 2012; 32:18–26.
65. Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 2007; 178:1357–62.
66. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499–506.
67. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce energy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009; 182:240–9.
68. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumour-bearing mice. J Immunol 2008; 181:5791–802.
69. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222:162–79.
70. Huang B, Pan PY, Li Q et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell energy in tumor-bearing host. Cancer Res 2006; 66:1123–31.
71. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 2015; 125:3356–64.
72. Verschoor CP, Johnstone J, Millar J et al. Blood CD33(+)HLA-DR(–) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol 2013; 93:633–7.]
73. Grizzle WE, Xu X, Zhang S et al. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev 2007; 128:672–80.
74. Enioutina EY, Bareyan D, Daynes RA. A role for immature myeloid cells in immune senescence. J Immunol 2011; 186:697–707.
75. Ishikawa S, Matsui Y, Wachi S, Yamaguchi H, Harashima N, Harada M. Age-associated impairment of antitumor immunity in carcinoma-bearing mice and restoration by oral administration of Lentinula edodes mycelia extract. Cancer Immunol Immunother 2016; 65:961–72.
76. Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 2012; 209:201–9.
77. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252–64.
78. Canaday DH, Parker KE, Aung H, Chen HE, Nunez-Medina D, Burant CJ. Age-dependent changes in the expression of regulatory cell surface ligands in activated human T-cells. BMC Immunol 2013; 14:45.
79. Channappanavar R, Twardy BS, Krishna P, Suvas S. Advancing age leads to predominance of inhibitory receptor expressing CD4 T cells. Mech Ageing Dev 2009; 130:709–12.
80. Mirza N, Duque MA, Dominguez AL, Schrum AG, Dong H, Lustgarten J. B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals. J Immunol 2010; 184:5466–74.
81. Shimada Y, Hayashi M, Nagasaka Y, Ohno-Iwashita Y, Inomata M. Age-associated up-regulation of a negative co-stimulatory receptor PD-1 in mouse CD4+ T cells. Exp Gerontol 2009; 44:517–22.
82. Hurez V, Dao V, Liu A et al. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell 2015; 14:945–56.
83. Lages CS, Lewkowich I, Sproles A, Wills-Karp M, Chougnet C. Partial restoration of T cell function in aged mice by in vitro blockade of the PD-1/PD-L1 pathway. Aging Cell 2010; 9:785–98.
84. Mannick JB, Del Giudice G, Lattanzi M et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014; 6:268ra179.
85. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443–54.
86. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793–800.
87. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455–65.
88. Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37.
89. Figueiredo ASP, Hurez V, Liu A. TJCJI. Age and sex affect αCTLA-4 efficacy alone and combined with αB7-H1 or regulatory T cell depletion in a melanoma model. J Immunol 2016; 196:213.4.
90. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–23.
91. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med 2015; 7:280ps7.
92. Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, Allison JP. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. J Immunol 2015; 194:2089–98.
93. Dao V, Liu Y, Pandeswara S et al. Immune stimulatory effects of rapamycin are mediated by stimulation of antitumor γδ T cells. Cancer Res, 2016; 76:5970–82.
94. Hasty P, Livi CB, Dodds SG et al. eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila) 2014; 7:169–78.
95. Pollizzi KN, Patel CH, Sun IH et al. mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation. J Clin Invest 2015; 125:2090–108.
96. Farazi M, Nguyen J, Goldufsky J et al. Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging. Cancer Immunol Immunother 2014; 63:615–26.
97. Di Biase S, Lee C, Brandhorst S et al. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. Cancer Cell 2016; 30:136–46.
98. Jackaman C, Nelson DJ. Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts? Exp Gerontol 2014; 54:53–7.
99. Begley LA, Kasina S, MacDonald J, Macoska JA. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008; 43:194–9.
100. Barron DA, Strand DW, Ressler SJ et al. TGF-beta1 induces an age-dependent inflammation of nerve ganglia and fibroplasia in the prostate gland stroma of a novel transgenic mouse. PLOS ONE 2010; 5:e13751.
101. Bianchi-Frias D, Vakar-Lopez F, Coleman IM, Plymate SR, Reed MJ, Nelson PS. The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLOS ONE 2010; 5:e12501.
102. Joudi FN, Smith BJ, O'Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 2006; 175:1634–9. discussion 9-40.
103. Margel D, Alkhateeb SS, Finelli A, Fleshner N. Diminished efficacy of bacille Calmette–Guerin among elderly patients with nonmuscle invasive bladder cancer. Urology 2011; 78:848–54.
104. Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette–Guerin therapy. Urology 2007; 70:65–8.
105. Yatsunenko T, Rey FE, Manary MJ et al. Human gut microbiome viewed across age and geography. Nature 2012; 486:222–7.
106. Pitt JM, Vetizou M, Waldschmitt N et al. Fine-tuning cancer immunotherapy: optimizing the gut microbiome. Cancer Res 2016; 76:4602–7.
107. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell 2016; 165:276–87.
108. Sivan A, Corrales L, Hubert N et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350:1084–9.
109. Vetizou M, Pitt JM, Daillere R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350:1079–84.
110. Viaud S, Saccheri F, Mignot G et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342:971–6.
111. Iida N, Dzutsev A, Stewart CA et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342:967–70.